{"ticker": {"uuid": "a7840756-d2cb-42a7-9423-6826b2a1ef82", "symbol": "LEXX", "name": "Lexaria Bioscience Corp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Lexaria Bioscience narrows Q3 loss to $(0.08) per share", "summary": "Lexaria Bioscience reported a Q3 loss per share of $(0.08), an improvement from $(0.21) last year, and better than the analyst estimate of $(0.09). This indicates effective expense management and progress in financial operations, though the company remains unprofitable. The artic", "url": "https://scanx.trade/stock-market-news/companies/lexaria-bioscience-narrows-q3-loss-to-0-08-per-share/45528360", "source_name": "scanx.trade", "published_at": "2026-07-13T23:10:42", "published_display": "13 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEXARIA BIOSCIENCE ($LEXX) Releases Q3 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQdnRvamxRaldLVS0zTE95SHkzenFxaFNCemItMlhrb2FKbGN1b3VVQjRRUzZaNkhYaG1IcjQxNk5kUVYtVGRwSTdQdTJHN3VfVVB5X05VdXczRlIyZFNMaHpjX3c1U1pLM1o2MHpyQXdFbDNrdERkXzR1YUZCREF3eE1WSkR4MFJDeVV3YkZ3RzdhZjU5eEE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-13T20:55:00+00:00", "published_display": "13 Jul 2026 20:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPTUViWXhleWNVcXliS1U0VGttU1dKWDRYSWV0N2J0VnNnZUFRcGMzMG5lbnl6SWdjVGxMR051ekNBTzItVWNJN1l2SVFnQlhVQmduQUYwSDdUc1JoUXR2VHhJb1RVX0RmaVZOTm1saml2Y1QzS19aU2J5amJWcEhqdlVXbHZ0U2liMFpNOWxPSTB1SUN2TUN3QmhqNGtSbHdCOE9WdW9EN0dBT1l1NjNuZURobzBjQmFXeVE0QjJRcE1MbzNTaUo4S3lfYThjck84N1R6LVpHUm81NTFrSWhqWGpzRmE5WG8?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-13T20:23:00+00:00", "published_display": "13 Jul 2026 20:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp. 2026: Revenue $0 EPS ($0.08) \u2014 10-Q Summary", "summary": "Lexaria Bioscience Corp. (LEXX) reported its 2026 quarterly results with $0 revenue and a diluted loss per share of ($0.08), though its net loss narrowed significantly from the prior year. The company is advancing R&D in GLP-1, GIP, glucagon, and CBD programs, and raised approxim", "url": "https://www.tradingview.com/news/tradingview:135774442d746:0-lexaria-bioscience-corp-2026-revenue-0-eps-0-08-10-q-summary/", "source_name": "TradingView", "published_at": "2026-07-13T20:10:42", "published_display": "13 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience (NASDAQ: LEXX) narrows loss but warns on cash and Nasdaq bid", "summary": "Lexaria Bioscience reported a narrower net loss of $5.0 million for the nine months ended May 31, 2026, compared to $9.2 million a year prior, primarily due to reduced R&D spending. Despite this, the company warned about its ability to continue as a going concern beyond Q1 fiscal", "url": "https://www.stocktitan.net/sec-filings/LEXX/10-q-lexaria-bioscience-corp-quarterly-earnings-report-664931e06cf9.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:10:41", "published_display": "13 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lexaria Updates Business Development", "summary": "Lexaria Bioscience Corp. (NASDAQ: LEXX) has reported positive outcomes from recent meetings at the 2026 BIO International Convention, focusing on partnerships for its DehydraTECH\u2122 drug delivery platform. The company noted a significant interest in the GLP-1 sector, particularly r", "url": "https://investingnews.com/lexaria-updates-business-development-2677162159/", "source_name": "Investing News Network", "published_at": "2026-07-07T06:11:06", "published_display": "07 Jul 2026 06:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria reports pharmaceutical partnership discussions at BIO By Investing.com", "summary": "Lexaria Bioscience Corp. (NASDAQ:LEXX) held discussions with potential pharmaceutical partners at the 2026 BIO International Convention, focusing on the GLP-1 sector and the company's DehydraTECH technology. Despite a stock decline, analysts predict profitability for Lexaria this", "url": "https://m.in.investing.com/news/stock-market-news/lexaria-reports-pharmaceutical-partnership-discussions-at-bio-93CH-5483377?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-06T15:40:37", "published_display": "06 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria pitches DehydraTECH to drugmakers at BIO as GLP-1 safety focus grows", "summary": "Lexaria Bioscience (NASDAQ: LEXX) reported successful business development meetings at the 2026 BIO International Convention, primarily focusing on GLP-1 drug applications and its DehydraTECH technology. The company noted a shift in industry focus towards balancing GLP-1 weight-l", "url": "https://www.stocktitan.net/news/LEXX/lexaria-updates-business-yp18bcvt8b1w.html", "source_name": "Stock Titan", "published_at": "2026-07-06T12:40:37", "published_display": "06 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEXX - Lexaria Bioscience Corp Forecast, Target Price", "summary": "This article provides a detailed financial overview and forecast for Lexaria Bioscience Corp (LEXX), including key financial metrics, stock performance data, and analyst recommendations. It highlights the company's last closing price, market capitalization, and various profitabil", "url": "https://finviz.com/stock?t=LEXX&ta=1&p=w&ty=fc&b=1", "source_name": "Finviz", "published_at": "2026-07-02T03:39:39", "published_display": "02 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp. Actuals & Estimates (NASDAQ:LEXX)", "summary": "This article provides an overview of Lexaria Bioscience Corp. (NASDAQ: LEXX) financial data and analyst estimates. It includes current stock price, historical performance, market capitalization, and upcoming earnings report dates. The company's stock has seen a decrease over the ", "url": "https://www.tradingview.com/symbols/NASDAQ-LEXX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:11:27", "published_display": "26 Jun 2026 07:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule", "summary": "Lexaria Bioscience Corp. has initiated dosing for its Human Pilot Study #7 (GLP-1-H26-7), evaluating two oral DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy\u00ae tablets. The 5-week study aims to confirm superior safety, tolerability, and pharmacokinetic performan", "url": "https://www.dailycorinthian.com/news/national/lexarias-human-study-glp-1-h26-7-has-begun-dosing-on-schedule/article_6ee6f1d3-7efe-5fae-b645-dd90a87111b6.html", "source_name": "The Daily Corinthian", "published_at": "2026-06-25T13:43:28", "published_display": "25 Jun 2026 13:43", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria starts 5-week human GLP-1 study using tablet and capsule forms", "summary": "Lexaria Bioscience Corp. has initiated a 5-week human pilot study (GLP-1-H26-7) to evaluate two oral DehydraTECH-semaglutide (DHT-sema) compositions in both tablet and capsule forms against Novo Nordisk's Wegovy tablets. The study, which began dosing on June 14, 2026, aims to ass", "url": "https://www.stocktitan.net/news/LEXX/lexaria-s-human-study-glp-1-h26-7-has-begun-dosing-on-c3k2wnizlx48.html", "source_name": "Stock Titan", "published_at": "2026-06-25T12:41:36", "published_display": "25 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Lexaria Bioscience Corp (LEXX), focusing on its support and resistance levels, various technical indicators, and moving averages. As of June 26, 2026, LEXX has a price momentum score of 5.64 and is suitable for range-bound swing tradi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexx/technical", "source_name": "TradingKey", "published_at": "2026-06-25T12:39:06", "published_display": "25 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "The article analyzes the financial health of Lexaria Bioscience Corp (LEXX), which currently has a financial score of 6.70 out of 10, ranking 139th in the Pharmaceuticals industry. Despite a robust overall financial status, the company exhibits low operating efficiency. Its lates", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-24T12:10:26", "published_display": "24 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule", "summary": "Lexaria Bioscience Corp. announced that its Animal Study GLP-1-A26-1, evaluating novel DehydraTECH-semaglutide and DehydraTECH-CBD compositions, has begun dosing on schedule. The study aims to develop alternative formulations to SNAC, currently used in Novo Nordisk's oral GLP-1 p", "url": "https://investingnews.com/lexaria-s-animal-study-glp-1-a26-1-has-begun-dosing-on-schedule/", "source_name": "Investing News Network", "published_at": "2026-06-23T14:10:42", "published_display": "23 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria starts animal GLP-1 study, adds Australian patent", "summary": "Lexaria Bioscience has begun dosing for Animal Study #1 (GLP-1-A26-1) on schedule, evaluating DehydraTECH-semaglutide and DehydraTECH-CBD GLP-1 compositions in rats to discover alternative formulations to SNAC for new intellectual property. Results are anticipated by early Septem", "url": "https://www.stocktitan.net/news/LEXX/lexaria-s-animal-study-glp-1-a26-1-has-begun-dosing-on-i3y4jphvqlg3.html", "source_name": "Stock Titan", "published_at": "2026-06-23T13:09:46", "published_display": "23 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp. Financial Disclosures & SEC Filings", "summary": "This article provides an extensive list of Lexaria Bioscience Corp.'s SEC filings and financial disclosures, including quarterly and annual earnings reports from 2020 to 2026. Each entry offers a brief summary of the company's financial performance, revenue, net losses, and R&D a", "url": "https://www.tradingview.com/symbols/NASDAQ-LEXX/documents/", "source_name": "TradingView", "published_at": "2026-06-18T23:09:46", "published_display": "18 Jun 2026 23:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXXW) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Lexaria Bioscience Corp (LEXXW), noting that key financial ratios such as P/E, P/B, P/S, and P/CF have not been disclosed by the company. It briefly outlines the stock's current price and market capitalization. The analysis from Trad", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexxw/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T19:10:24", "published_display": "18 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Lexaria Bioscience Corp (LEXXW), detailing its support, resistance, various technical indicators, and moving averages. It highlights that no buy or sell signals are currently indicated by the technical indicators or moving averages, w", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexxw/technical", "source_name": "TradingKey", "published_at": "2026-06-18T18:10:24", "published_display": "18 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXXW) Institutional Confidence \u2014 TradingKey", "summary": "This article provides an overview of the institutional confidence in Lexaria Bioscience Corp (LEXXW), detailing changes in institutional shareholding. Key investors like Clear Street Group Inc. and HRT Financial LP have increased their stake, while others like Heights Capital Man", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexxw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T07:09:04", "published_display": "18 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Lexaria Bioscience Corp (LEXX), including its business segments, regional revenue, and profit contribution. The report indicates that relevant financial data for these categories have not yet been disclosed by the comp", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexx/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T07:09:03", "published_display": "18 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXXW) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Lexaria Bioscience Corp (LEXXW) from TradingKey. It indicates that relevant data for EPS, revenue, and net profit forecasting have not yet been disclosed by the company. The article serves as a placeholder for future financial growth", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexxw/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:42", "published_display": "17 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Lexaria Bioscience Corp (LEXX) has an earnings forecast score of 8.00, placing it 55th in the Pharmaceuticals industry. Analysts have set an average price target of $6.00, with a range from $4.00 to $6.00, and a \"Buy\" rating based on one analyst. The company's expected revenue fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:42", "published_display": "17 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria says GLP-1 drugs are moving into more diseases and markets", "summary": "Lexaria Bioscience reports on the accelerating adoption and expanding indications for GLP-1 drugs, noting their increasing use for weight loss and various comorbidity treatments. The company highlights its DehydraTECH platform's potential to improve oral GLP-1 absorption and redu", "url": "https://www.stocktitan.net/news/LEXX/glp-1-arms-race-intensifies-as-the-addressable-markets-continue-to-o933dygl91fr.html", "source_name": "Stock Titan", "published_at": "2026-06-17T13:40:03", "published_display": "17 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexarias-animal-study-examining-next-132500246.html", "source_name": "ACCESS Newswire", "published_at": "2026-06-09T13:25:00+00:00", "published_display": "09 Jun 2026 13:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexaria-attending-bio-international-convention-132500125.html", "source_name": "ACCESS Newswire", "published_at": "2026-06-03T13:25:00+00:00", "published_display": "03 Jun 2026 13:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria drug platform sees record partner interest ahead of BIO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQQU9kS0FUc0RfTnJEQmNlWWY5UHFrS3hxb0JEUV9EMnF4OThPXzd3RVY2Wi1CVVBBU3FQWndjd1c4OE1rRFdJdGliQ3dqVU5CR1YzOXNaanNxd0lVUHRrbjdNclNCSlg1RWNYdDhmUHl3VmlkRUprekpMOXl3T3JOLTFhaTd0VmgyMUZ2SHhvX1pyMzZiYXgzeUJzU0N2UXdBdENfVnFVdjRCYTJ0YTZCbWFwMjdqeXQzN1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexaria-receives-independent-review-board-131500724.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-19T13:15:00+00:00", "published_display": "19 May 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lexaria Updates Progress on Human Study #7", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexaria-updates-progress-human-study-131000601.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-05T13:10:00+00:00", "published_display": "05 May 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria targets mid-June start for 5-week oral semaglutide study", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPN0hZczFsbWhGY3ptZEFkSVNrUHpkYnhEdWxybU1LdnBFRzEyYzhsdXhKUXF3NlQtbW1oMThZM05UMzQ4NWZ6bWxReUx5Z1BGWTJwdmtBWFlHeURBV0tETVFGeDBWQjJKMVF4cm44MG9YbXF3MzJzY3FlOXVQRzhiUUt5UXN3cklUcFJfcExVMnBNc2p1YWNUN093?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexaria-bioscience-launches-ongoing-investor-132500875.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-01T13:25:00+00:00", "published_display": "01 May 2026 13:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Can Lexaria Bioscience (NASDAQ:LEXX) Afford To Invest In Growth?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience (NASDAQ:LEXX) Will Have To Spend Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPQlpsTWpLV2twbU1qYVlNeFpZdHUxNjJGaE51SDB5aFJqdjVOYUdFbUhtblZsd0MyeWRGUE94Tm5ObTZyN0dwMTA0Rlo2MEMzczFYbEZaNkxQV1lvQTZNUzhfdV85R0V6djQybWVlR3lpNG9UV2Z6a3dBTUYwOWxBeXE1VFA2WHB3QVFaQVZnR3YxUUFNZzNyX0JvTXlqTHZwOUtZ?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEXARIA BIOSCIENCE ($LEXX) Releases Q2 2026 Earnings | LEXX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPQm10ZTZKM1ZRcWNucHRLMEs0SG1oNXZlek44ZU5keVRFVm9uNzlhN2hSdUlfZGFScUZSS0x3bTlOdjYwQ3NkTUZBSnd1ZmhJd2VXLUgtMU5XWmQySzZveFByWE9SRV93UE0zdVl2cUQ4Z191Yk1rTVJvS09kbkpzblRHZzlhYzJLNy1JM29aUU9lcTRhMlE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A third oral GLP-1 wins FDA approval, and Lexaria sees an opening", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPN01sb01YZV9zU2Ytc3U4MlpwLXJ0Ul9zRDRtcWNJNjlpNFFGOE1BVmI4YlBfNXhuQWRIbGZhcm9KRGlQUGFsQVRldS1ZXzRQbksyQUpjWXRMNi1majBmcnp2cVh5Q1dBeTZPUWZvcjBhVG9ZaU96SUV6U2k0VmwwejJxSHdkblpTWEw5NVZRdk5LQkcxREFCN040X2pxZkNieUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxORWFCUEdURHJHaUM4a2xXc2NkODg0VnRsc2dRbWdDeVBhd2pDWTdzMkZ2a1A4Y3kyUkV3dlo4Q3ZKRThxYW1RVFNoajU3TFlqcDYtQzNJNU0taTZvV3gta3I1eHlwZkFxUVdKYTBRRy1YOC05c1U2YU9XdEFZeXRzbjY1SGNVX3dCNUpWVUtDNVhHVkpkWk02VGsydUdfY2FheHRvSDJxNGJKNUM3SGdBbkF1dHFvTl9pNzRtWmtLVnA3RnRUYWcwMU9xNHZlRFRuUzE0RUYyR3RoUnB4UWxyRS03LU8?oc=5", "source_name": "Investing News Network", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience (LEXX) Expands Global Patent Portfolio with N", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQd1BlS2NMd0pCcG15OXdZYmJhRTh2NzE5YWI0SWNGV2syNHVYRWhVRE56Zm9Icl93MDZKMW9lTHdvbkxvWm9SWk8xYmMzZkdTNjhWOVIxSHJpRl8zaHZORTFUVnpMYVhUa1VpY1pfTmJ4RGhjQnZkcUpqRDVsaXZLTGR6MlFUaTNfYnpPRzluSmRNRV9JeE45Q3V0Um9lMEhOYkVRaWFJbnZlV2xydGFlYnJ0WWFZbHJ3VXczUFlRZHhnUWYyYWJNTU5jV3RzM3ZqQjlVWG9R?oc=5", "source_name": "GuruFocus", "published_at": "2025-06-23T07:00:00+00:00", "published_display": "23 Jun 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTFBEa1lCQUdGTXA3eFRCR1NLWHFzc1c2UzBYQlBEbkZJRXJoVERBUGtwZFR0c1ZBSHR6aXN6Z25DaXI5bjMxbVkxM19UZmpaOUhMNzlYdmltYUx2bUxqVWJCb1owZEZpeHRHVXE3VA?oc=5", "source_name": "Investing News Network", "published_at": "2023-04-13T11:47:54+00:00", "published_display": "13 Apr 2023 11:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp. Discusses $11 Million Public Offering and 2021 Goals with The Stock Day Podcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTFBTN19wMWxLeDIxZ1F0dmR6NW9QcjBaWlktVHJqYTRSaFhncThpNkxCb1c5b050dDFHQ2JhVDhKSzdOWWFPZk1VemlJd3ZuaVZKQ2U0RnpIbzNmZGVnQ1Vr?oc=5", "source_name": "TMX Newsfile", "published_at": "2021-01-28T08:00:00+00:00", "published_display": "28 Jan 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience (LEXX) Stock Price, News & Analysis $LEXX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9mVWZSdm1ybUlXaElqOEtVUXpveDN6bXFsX2pzQWMwMnEtcG11MFRQMDV3OTRPal9oR3lCWW5xWUZTdnVmczIydE9LUDlObThoN1NDZFFYdUMtUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-01-17T01:03:55+00:00", "published_display": "17 Jan 2021 01:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience (LEXX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE95UTB0b0R3WDFqMFJmZjRKd25TN1pmOXd2QlRTSmtMMGtjbjdxbllibzVvZnhPbkRMQ0ZlbmJwRWd1eUZWSHVhZlNWVVBiWk0?oc=5", "source_name": "Zacks Investment Research", "published_at": "2021-01-14T12:04:34+00:00", "published_display": "14 Jan 2021 12:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEXX Stock Price and Chart \u2014 NASDAQ:LEXX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9OUnZOMXhlY1lRTlVlSHozOUhxMnRheEllUmU3Ukk4VGJLbmFJQzBqZWJ3WWFyaGY1YThBX3VGRzhxb00ybmJ6SEdwb3h3MjhDUVhLaVJYV0xUSzhN?oc=5", "source_name": "TradingView", "published_at": "2021-01-12T19:16:53+00:00", "published_display": "12 Jan 2021 19:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxOUW9iUy16Y0NmclRiQ3U2T1JqV21xU3BzbDNVamtGa0xmT2JfUGtvUTgwZm1jUXVzbzJtXzFLcjNfOWtYUUdQS2kyYXdDeHFxY1ZnRjlLWDJsTXJzRzM1djZtei1GOEhuNUtxa29xT2dsQ0lqU2FZOWktYlVVM1YtLUYzZ3ppTmc0ZnRPNzNIOEJpOHJ0WjJDMGNEMW9RcVJTQkFwRTFqclVyOGZ1TVotOVJ5TkE0dlRzV1prbk52eERXM3loWVUxZjBxaEZFWkduX1FXaFNMVVRFY1JCVU9iYVpQVk9qdzVmQkRLV2xsUWVQakJPN2ZVdGlWR1NiQQ?oc=5", "source_name": "Investing News Network", "published_at": "2021-01-11T08:00:00+00:00", "published_display": "11 Jan 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Welcomes New Medical Marijuana Expert Advisor", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOSHZxMVZhd0Z6NFhiZ2h3dzRaeUUzeTBMQkNHSFRRR2pSb0x5UHZmdk5LYjhPOUtwM0EzWVM0dTlmdFRLUXFZOUF2eFFCejlqYUViYV9tNHp4eExMckVqZ2g2MTZRMlg4WEw2LWUxOFFGZ0NJLVhraFZqZTMwT2lVSWNrSG5UMUZnVEZzTGdqRmxkWnBPbm9UTk9oMA?oc=5", "source_name": "TMX Newsfile", "published_at": "2014-03-25T07:00:00+00:00", "published_display": "25 Mar 2014 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Lexaria Bioscience narrows Q3 loss to $(0.08) per share", "summary": "Lexaria Bioscience reported a Q3 loss per share of $(0.08), an improvement from $(0.21) last year, and better than the analyst estimate of $(0.09). This indicates effective expense management and progress in financial operations, though the company remains unprofitable. The artic", "url": "https://scanx.trade/stock-market-news/companies/lexaria-bioscience-narrows-q3-loss-to-0-08-per-share/45528360", "source_name": "scanx.trade", "published_at": "2026-07-13T23:10:42", "published_display": "13 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEXARIA BIOSCIENCE ($LEXX) Releases Q3 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQdnRvamxRaldLVS0zTE95SHkzenFxaFNCemItMlhrb2FKbGN1b3VVQjRRUzZaNkhYaG1IcjQxNk5kUVYtVGRwSTdQdTJHN3VfVVB5X05VdXczRlIyZFNMaHpjX3c1U1pLM1o2MHpyQXdFbDNrdERkXzR1YUZCREF3eE1WSkR4MFJDeVV3YkZ3RzdhZjU5eEE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-13T20:55:00+00:00", "published_display": "13 Jul 2026 20:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPTUViWXhleWNVcXliS1U0VGttU1dKWDRYSWV0N2J0VnNnZUFRcGMzMG5lbnl6SWdjVGxMR051ekNBTzItVWNJN1l2SVFnQlhVQmduQUYwSDdUc1JoUXR2VHhJb1RVX0RmaVZOTm1saml2Y1QzS19aU2J5amJWcEhqdlVXbHZ0U2liMFpNOWxPSTB1SUN2TUN3QmhqNGtSbHdCOE9WdW9EN0dBT1l1NjNuZURobzBjQmFXeVE0QjJRcE1MbzNTaUo4S3lfYThjck84N1R6LVpHUm81NTFrSWhqWGpzRmE5WG8?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-13T20:23:00+00:00", "published_display": "13 Jul 2026 20:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp. 2026: Revenue $0 EPS ($0.08) \u2014 10-Q Summary", "summary": "Lexaria Bioscience Corp. (LEXX) reported its 2026 quarterly results with $0 revenue and a diluted loss per share of ($0.08), though its net loss narrowed significantly from the prior year. The company is advancing R&D in GLP-1, GIP, glucagon, and CBD programs, and raised approxim", "url": "https://www.tradingview.com/news/tradingview:135774442d746:0-lexaria-bioscience-corp-2026-revenue-0-eps-0-08-10-q-summary/", "source_name": "TradingView", "published_at": "2026-07-13T20:10:42", "published_display": "13 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience (NASDAQ: LEXX) narrows loss but warns on cash and Nasdaq bid", "summary": "Lexaria Bioscience reported a narrower net loss of $5.0 million for the nine months ended May 31, 2026, compared to $9.2 million a year prior, primarily due to reduced R&D spending. Despite this, the company warned about its ability to continue as a going concern beyond Q1 fiscal", "url": "https://www.stocktitan.net/sec-filings/LEXX/10-q-lexaria-bioscience-corp-quarterly-earnings-report-664931e06cf9.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:10:41", "published_display": "13 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Updates Business Development", "summary": "Lexaria Bioscience Corp. (NASDAQ: LEXX) has reported positive outcomes from recent meetings at the 2026 BIO International Convention, focusing on partnerships for its DehydraTECH\u2122 drug delivery platform. The company noted a significant interest in the GLP-1 sector, particularly r", "url": "https://investingnews.com/lexaria-updates-business-development-2677162159/", "source_name": "Investing News Network", "published_at": "2026-07-07T06:11:06", "published_display": "07 Jul 2026 06:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria reports pharmaceutical partnership discussions at BIO By Investing.com", "summary": "Lexaria Bioscience Corp. (NASDAQ:LEXX) held discussions with potential pharmaceutical partners at the 2026 BIO International Convention, focusing on the GLP-1 sector and the company's DehydraTECH technology. Despite a stock decline, analysts predict profitability for Lexaria this", "url": "https://m.in.investing.com/news/stock-market-news/lexaria-reports-pharmaceutical-partnership-discussions-at-bio-93CH-5483377?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-06T15:40:37", "published_display": "06 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria pitches DehydraTECH to drugmakers at BIO as GLP-1 safety focus grows", "summary": "Lexaria Bioscience (NASDAQ: LEXX) reported successful business development meetings at the 2026 BIO International Convention, primarily focusing on GLP-1 drug applications and its DehydraTECH technology. The company noted a shift in industry focus towards balancing GLP-1 weight-l", "url": "https://www.stocktitan.net/news/LEXX/lexaria-updates-business-yp18bcvt8b1w.html", "source_name": "Stock Titan", "published_at": "2026-07-06T12:40:37", "published_display": "06 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEXX - Lexaria Bioscience Corp Forecast, Target Price", "summary": "This article provides a detailed financial overview and forecast for Lexaria Bioscience Corp (LEXX), including key financial metrics, stock performance data, and analyst recommendations. It highlights the company's last closing price, market capitalization, and various profitabil", "url": "https://finviz.com/stock?t=LEXX&ta=1&p=w&ty=fc&b=1", "source_name": "Finviz", "published_at": "2026-07-02T03:39:39", "published_display": "02 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp. Actuals & Estimates (NASDAQ:LEXX)", "summary": "This article provides an overview of Lexaria Bioscience Corp. (NASDAQ: LEXX) financial data and analyst estimates. It includes current stock price, historical performance, market capitalization, and upcoming earnings report dates. The company's stock has seen a decrease over the ", "url": "https://www.tradingview.com/symbols/NASDAQ-LEXX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:11:27", "published_display": "26 Jun 2026 07:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule", "summary": "Lexaria Bioscience Corp. has initiated dosing for its Human Pilot Study #7 (GLP-1-H26-7), evaluating two oral DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy\u00ae tablets. The 5-week study aims to confirm superior safety, tolerability, and pharmacokinetic performan", "url": "https://www.dailycorinthian.com/news/national/lexarias-human-study-glp-1-h26-7-has-begun-dosing-on-schedule/article_6ee6f1d3-7efe-5fae-b645-dd90a87111b6.html", "source_name": "The Daily Corinthian", "published_at": "2026-06-25T13:43:28", "published_display": "25 Jun 2026 13:43", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria starts 5-week human GLP-1 study using tablet and capsule forms", "summary": "Lexaria Bioscience Corp. has initiated a 5-week human pilot study (GLP-1-H26-7) to evaluate two oral DehydraTECH-semaglutide (DHT-sema) compositions in both tablet and capsule forms against Novo Nordisk's Wegovy tablets. The study, which began dosing on June 14, 2026, aims to ass", "url": "https://www.stocktitan.net/news/LEXX/lexaria-s-human-study-glp-1-h26-7-has-begun-dosing-on-c3k2wnizlx48.html", "source_name": "Stock Titan", "published_at": "2026-06-25T12:41:36", "published_display": "25 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Lexaria Bioscience Corp (LEXX), focusing on its support and resistance levels, various technical indicators, and moving averages. As of June 26, 2026, LEXX has a price momentum score of 5.64 and is suitable for range-bound swing tradi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexx/technical", "source_name": "TradingKey", "published_at": "2026-06-25T12:39:06", "published_display": "25 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "The article analyzes the financial health of Lexaria Bioscience Corp (LEXX), which currently has a financial score of 6.70 out of 10, ranking 139th in the Pharmaceuticals industry. Despite a robust overall financial status, the company exhibits low operating efficiency. Its lates", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-24T12:10:26", "published_display": "24 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule", "summary": "Lexaria Bioscience Corp. announced that its Animal Study GLP-1-A26-1, evaluating novel DehydraTECH-semaglutide and DehydraTECH-CBD compositions, has begun dosing on schedule. The study aims to develop alternative formulations to SNAC, currently used in Novo Nordisk's oral GLP-1 p", "url": "https://investingnews.com/lexaria-s-animal-study-glp-1-a26-1-has-begun-dosing-on-schedule/", "source_name": "Investing News Network", "published_at": "2026-06-23T14:10:42", "published_display": "23 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria starts animal GLP-1 study, adds Australian patent", "summary": "Lexaria Bioscience has begun dosing for Animal Study #1 (GLP-1-A26-1) on schedule, evaluating DehydraTECH-semaglutide and DehydraTECH-CBD GLP-1 compositions in rats to discover alternative formulations to SNAC for new intellectual property. Results are anticipated by early Septem", "url": "https://www.stocktitan.net/news/LEXX/lexaria-s-animal-study-glp-1-a26-1-has-begun-dosing-on-i3y4jphvqlg3.html", "source_name": "Stock Titan", "published_at": "2026-06-23T13:09:46", "published_display": "23 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp. Financial Disclosures & SEC Filings", "summary": "This article provides an extensive list of Lexaria Bioscience Corp.'s SEC filings and financial disclosures, including quarterly and annual earnings reports from 2020 to 2026. Each entry offers a brief summary of the company's financial performance, revenue, net losses, and R&D a", "url": "https://www.tradingview.com/symbols/NASDAQ-LEXX/documents/", "source_name": "TradingView", "published_at": "2026-06-18T23:09:46", "published_display": "18 Jun 2026 23:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXXW) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Lexaria Bioscience Corp (LEXXW), noting that key financial ratios such as P/E, P/B, P/S, and P/CF have not been disclosed by the company. It briefly outlines the stock's current price and market capitalization. The analysis from Trad", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexxw/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T19:10:24", "published_display": "18 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Lexaria Bioscience Corp (LEXXW), detailing its support, resistance, various technical indicators, and moving averages. It highlights that no buy or sell signals are currently indicated by the technical indicators or moving averages, w", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexxw/technical", "source_name": "TradingKey", "published_at": "2026-06-18T18:10:24", "published_display": "18 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXXW) Institutional Confidence \u2014 TradingKey", "summary": "This article provides an overview of the institutional confidence in Lexaria Bioscience Corp (LEXXW), detailing changes in institutional shareholding. Key investors like Clear Street Group Inc. and HRT Financial LP have increased their stake, while others like Heights Capital Man", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexxw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T07:09:04", "published_display": "18 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Lexaria Bioscience Corp (LEXX), including its business segments, regional revenue, and profit contribution. The report indicates that relevant financial data for these categories have not yet been disclosed by the comp", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexx/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T07:09:03", "published_display": "18 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXXW) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Lexaria Bioscience Corp (LEXXW) from TradingKey. It indicates that relevant data for EPS, revenue, and net profit forecasting have not yet been disclosed by the company. The article serves as a placeholder for future financial growth", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexxw/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:42", "published_display": "17 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp (LEXX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Lexaria Bioscience Corp (LEXX) has an earnings forecast score of 8.00, placing it 55th in the Pharmaceuticals industry. Analysts have set an average price target of $6.00, with a range from $4.00 to $6.00, and a \"Buy\" rating based on one analyst. The company's expected revenue fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lexx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:42", "published_display": "17 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria says GLP-1 drugs are moving into more diseases and markets", "summary": "Lexaria Bioscience reports on the accelerating adoption and expanding indications for GLP-1 drugs, noting their increasing use for weight loss and various comorbidity treatments. The company highlights its DehydraTECH platform's potential to improve oral GLP-1 absorption and redu", "url": "https://www.stocktitan.net/news/LEXX/glp-1-arms-race-intensifies-as-the-addressable-markets-continue-to-o933dygl91fr.html", "source_name": "Stock Titan", "published_at": "2026-06-17T13:40:03", "published_display": "17 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexarias-animal-study-examining-next-132500246.html", "source_name": "ACCESS Newswire", "published_at": "2026-06-09T13:25:00+00:00", "published_display": "09 Jun 2026 13:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexaria-attending-bio-international-convention-132500125.html", "source_name": "ACCESS Newswire", "published_at": "2026-06-03T13:25:00+00:00", "published_display": "03 Jun 2026 13:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria drug platform sees record partner interest ahead of BIO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQQU9kS0FUc0RfTnJEQmNlWWY5UHFrS3hxb0JEUV9EMnF4OThPXzd3RVY2Wi1CVVBBU3FQWndjd1c4OE1rRFdJdGliQ3dqVU5CR1YzOXNaanNxd0lVUHRrbjdNclNCSlg1RWNYdDhmUHl3VmlkRUprekpMOXl3T3JOLTFhaTd0VmgyMUZ2SHhvX1pyMzZiYXgzeUJzU0N2UXdBdENfVnFVdjRCYTJ0YTZCbWFwMjdqeXQzN1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexaria-receives-independent-review-board-131500724.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-19T13:15:00+00:00", "published_display": "19 May 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Updates Progress on Human Study #7", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexaria-updates-progress-human-study-131000601.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-05T13:10:00+00:00", "published_display": "05 May 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria targets mid-June start for 5-week oral semaglutide study", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPN0hZczFsbWhGY3ptZEFkSVNrUHpkYnhEdWxybU1LdnBFRzEyYzhsdXhKUXF3NlQtbW1oMThZM05UMzQ4NWZ6bWxReUx5Z1BGWTJwdmtBWFlHeURBV0tETVFGeDBWQjJKMVF4cm44MG9YbXF3MzJzY3FlOXVQRzhiUUt5UXN3cklUcFJfcExVMnBNc2p1YWNUN093?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexaria-bioscience-launches-ongoing-investor-132500875.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-01T13:25:00+00:00", "published_display": "01 May 2026 13:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Lexaria Bioscience (NASDAQ:LEXX) Afford To Invest In Growth?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience (NASDAQ:LEXX) Will Have To Spend Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPQlpsTWpLV2twbU1qYVlNeFpZdHUxNjJGaE51SDB5aFJqdjVOYUdFbUhtblZsd0MyeWRGUE94Tm5ObTZyN0dwMTA0Rlo2MEMzczFYbEZaNkxQV1lvQTZNUzhfdV85R0V6djQybWVlR3lpNG9UV2Z6a3dBTUYwOWxBeXE1VFA2WHB3QVFaQVZnR3YxUUFNZzNyX0JvTXlqTHZwOUtZ?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEXARIA BIOSCIENCE ($LEXX) Releases Q2 2026 Earnings | LEXX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPQm10ZTZKM1ZRcWNucHRLMEs0SG1oNXZlek44ZU5keVRFVm9uNzlhN2hSdUlfZGFScUZSS0x3bTlOdjYwQ3NkTUZBSnd1ZmhJd2VXLUgtMU5XWmQySzZveFByWE9SRV93UE0zdVl2cUQ4Z191Yk1rTVJvS09kbkpzblRHZzlhYzJLNy1JM29aUU9lcTRhMlE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A third oral GLP-1 wins FDA approval, and Lexaria sees an opening", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPN01sb01YZV9zU2Ytc3U4MlpwLXJ0Ul9zRDRtcWNJNjlpNFFGOE1BVmI4YlBfNXhuQWRIbGZhcm9KRGlQUGFsQVRldS1ZXzRQbksyQUpjWXRMNi1majBmcnp2cVh5Q1dBeTZPUWZvcjBhVG9ZaU96SUV6U2k0VmwwejJxSHdkblpTWEw5NVZRdk5LQkcxREFCN040X2pxZkNieUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxORWFCUEdURHJHaUM4a2xXc2NkODg0VnRsc2dRbWdDeVBhd2pDWTdzMkZ2a1A4Y3kyUkV3dlo4Q3ZKRThxYW1RVFNoajU3TFlqcDYtQzNJNU0taTZvV3gta3I1eHlwZkFxUVdKYTBRRy1YOC05c1U2YU9XdEFZeXRzbjY1SGNVX3dCNUpWVUtDNVhHVkpkWk02VGsydUdfY2FheHRvSDJxNGJKNUM3SGdBbkF1dHFvTl9pNzRtWmtLVnA3RnRUYWcwMU9xNHZlRFRuUzE0RUYyR3RoUnB4UWxyRS03LU8?oc=5", "source_name": "Investing News Network", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience (LEXX) Expands Global Patent Portfolio with N", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQd1BlS2NMd0pCcG15OXdZYmJhRTh2NzE5YWI0SWNGV2syNHVYRWhVRE56Zm9Icl93MDZKMW9lTHdvbkxvWm9SWk8xYmMzZkdTNjhWOVIxSHJpRl8zaHZORTFUVnpMYVhUa1VpY1pfTmJ4RGhjQnZkcUpqRDVsaXZLTGR6MlFUaTNfYnpPRzluSmRNRV9JeE45Q3V0Um9lMEhOYkVRaWFJbnZlV2xydGFlYnJ0WWFZbHJ3VXczUFlRZHhnUWYyYWJNTU5jV3RzM3ZqQjlVWG9R?oc=5", "source_name": "GuruFocus", "published_at": "2025-06-23T07:00:00+00:00", "published_display": "23 Jun 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTFBEa1lCQUdGTXA3eFRCR1NLWHFzc1c2UzBYQlBEbkZJRXJoVERBUGtwZFR0c1ZBSHR6aXN6Z25DaXI5bjMxbVkxM19UZmpaOUhMNzlYdmltYUx2bUxqVWJCb1owZEZpeHRHVXE3VA?oc=5", "source_name": "Investing News Network", "published_at": "2023-04-13T11:47:54+00:00", "published_display": "13 Apr 2023 11:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp. Discusses $11 Million Public Offering and 2021 Goals with The Stock Day Podcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTFBTN19wMWxLeDIxZ1F0dmR6NW9QcjBaWlktVHJqYTRSaFhncThpNkxCb1c5b050dDFHQ2JhVDhKSzdOWWFPZk1VemlJd3ZuaVZKQ2U0RnpIbzNmZGVnQ1Vr?oc=5", "source_name": "TMX Newsfile", "published_at": "2021-01-28T08:00:00+00:00", "published_display": "28 Jan 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience (LEXX) Stock Price, News & Analysis $LEXX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9mVWZSdm1ybUlXaElqOEtVUXpveDN6bXFsX2pzQWMwMnEtcG11MFRQMDV3OTRPal9oR3lCWW5xWUZTdnVmczIydE9LUDlObThoN1NDZFFYdUMtUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-01-17T01:03:55+00:00", "published_display": "17 Jan 2021 01:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience (LEXX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE95UTB0b0R3WDFqMFJmZjRKd25TN1pmOXd2QlRTSmtMMGtjbjdxbllibzVvZnhPbkRMQ0ZlbmJwRWd1eUZWSHVhZlNWVVBiWk0?oc=5", "source_name": "Zacks Investment Research", "published_at": "2021-01-14T12:04:34+00:00", "published_display": "14 Jan 2021 12:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LEXX Stock Price and Chart \u2014 NASDAQ:LEXX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9OUnZOMXhlY1lRTlVlSHozOUhxMnRheEllUmU3Ukk4VGJLbmFJQzBqZWJ3WWFyaGY1YThBX3VGRzhxb00ybmJ6SEdwb3h3MjhDUVhLaVJYV0xUSzhN?oc=5", "source_name": "TradingView", "published_at": "2021-01-12T19:16:53+00:00", "published_display": "12 Jan 2021 19:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxOUW9iUy16Y0NmclRiQ3U2T1JqV21xU3BzbDNVamtGa0xmT2JfUGtvUTgwZm1jUXVzbzJtXzFLcjNfOWtYUUdQS2kyYXdDeHFxY1ZnRjlLWDJsTXJzRzM1djZtei1GOEhuNUtxa29xT2dsQ0lqU2FZOWktYlVVM1YtLUYzZ3ppTmc0ZnRPNzNIOEJpOHJ0WjJDMGNEMW9RcVJTQkFwRTFqclVyOGZ1TVotOVJ5TkE0dlRzV1prbk52eERXM3loWVUxZjBxaEZFWkduX1FXaFNMVVRFY1JCVU9iYVpQVk9qdzVmQkRLV2xsUWVQakJPN2ZVdGlWR1NiQQ?oc=5", "source_name": "Investing News Network", "published_at": "2021-01-11T08:00:00+00:00", "published_display": "11 Jan 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexaria Welcomes New Medical Marijuana Expert Advisor", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOSHZxMVZhd0Z6NFhiZ2h3dzRaeUUzeTBMQkNHSFRRR2pSb0x5UHZmdk5LYjhPOUtwM0EzWVM0dTlmdFRLUXFZOUF2eFFCejlqYUViYV9tNHp4eExMckVqZ2g2MTZRMlg4WEw2LWUxOFFGZ0NJLVhraFZqZTMwT2lVSWNrSG5UMUZnVEZzTGdqRmxkWnBPbm9UTk9oMA?oc=5", "source_name": "TMX Newsfile", "published_at": "2014-03-25T07:00:00+00:00", "published_display": "25 Mar 2014 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 52, "sentiment_summary": {"positive": 14, "negative": 6, "neutral": 32, "score": 54, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 14.65, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 8.8, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}], "positive_events": 14, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 0.65, "latest_week": "2026-07-10", "one_week_move": 15.4, "four_week_move": 5.2, "twelve_week_move": -37.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.858691, "market_dynamics_buy_signal": false, "relative_strength": -33.739131, "fair_value_gap": -60.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.138, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+15.4% over one week, +5.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 8}, {"label": "TradingKey", "count": 8}, {"label": "Market source", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "Investing News Network", "count": 5}, {"label": "ACCESS Newswire", "count": 5}, {"label": "simplywall.st", "count": 3}, {"label": "Quiver Quantitative", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Regulatory and legal", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+15.4% over one week, +5.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Lexaria Bioscience narrows Q3 loss to $(0.08) per share"}], "updated_at": "2026-07-16T13:32:17.239345+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}